Sinonasal Neuroendocrine Carcinoma: 15 Years of Experience at a Single Institution
Journal of Neurological Surgery Part B: Skull Base · 2023-02 · 84 (01) · 051-059
DOI: 10.1055/s-0041-1740968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, 2023-02. Verfasst von Charles A Keilin und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor, Michigan, United States. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
Sinonasal neuroendocrine carcinomas (SNECs) are among the rarest paranasal sinus cancers. Consensus guidelines for therapy are difficult to develop due to limited data regarding the natural history and successful treatment of these tumors. This study presents 15 years of experience treating SNEC at a single institution and a review of the literature.
Design
Retrospective review.
Setting
Academic medical center in the United States.
Participants
Patients diagnosed with primary SNEC. Main Outcome Measures Overall survival.
Results
Thirteen patients were identified and included. Overall estimated survival was 74.6% at 5 years. Ten of 13 (76.9%) patients were diagnosed with high-grade neuroendocrine carcinoma and three (23.1%) with intermediate or low grade. All three patients with low- or intermediate-grade cancer survived more than 10 years from their initial diagnosis (median survival: 11.6 years) and are currently alive. The four patients who died had high-grade carcinoma, and estimated overall 5-year survival for all patients with high-grade carcinomas was 65.6%. Five patients, all with high-grade carcinoma, of seven who completed primary chemoradiation therapy (CRT) required salvage resection, and 60% are alive without disease.
Conclusion
This cohort has a higher overall rate of survival than many recent case series and reviews. There is consensus that multimodal therapy is preferred over monotherapy, but approaches to treatment vary widely. Our approach of surgical resection as primary therapy for low-grade tumors and primary CRT for high-grade SNEC has been successful, and could indicate hope for improved survival among these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Michigan Medical School, Ann Arbor, Michigan, United States.
- Division of Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, Ohio, United States.
- Department of Neurosurgery, The Ohio State University, Columbus, Ohio, United States.
- Department of Pathology, Michigan Medicine, Ann Arbor, Michigan, United States.
- Division of Skull Base Surgery and Rhinology, Department of Otolaryngology-Head and Neck Surgery, Michigan Medicine, Ann Arbor, Michigan, United States.
- Department of Neurosurgery, Michigan Medicine, Ann Arbor, Michigan, United States.
ORCID-Profile: Charles A Keilin
Zitieren
APA
Keilin, C. A., VanKoevering, K. K., McHugh, J. B., & McKean, E. L. (2023). Sinonasal Neuroendocrine Carcinoma: 15 Years of Experience at a Single Institution. Journal of Neurological Surgery Part B: Skull Base, 84(01), 051-059. https://doi.org/10.1055/s-0041-1740968
Vancouver
Keilin CA, VanKoevering KK, McHugh JB, McKean EL. Sinonasal Neuroendocrine Carcinoma: 15 Years of Experience at a Single Institution. Journal of Neurological Surgery Part B: Skull Base. 2023;84(01):051-059. doi:10.1055/s-0041-1740968
BibTeX
@article{Keilin2023,
author = {Keilin, Charles A and VanKoevering, Kyle K and McHugh, Jonathan B and McKean, Erin L},
title = {Sinonasal Neuroendocrine Carcinoma: 15 Years of Experience at a Single Institution},
journal = {Journal of Neurological Surgery Part B: Skull Base},
year = {2023},
volume = {84},
number = {01},
pages = {051--059},
doi = {10.1055/s-0041-1740968}
}
EUVIMED